Press releases
- AbCellera Reports Q1 2024 Business Results
- AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
- AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
- AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
- AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
- AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
- AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
More ▼
Key statistics
As of last trade Abcellera Biologics Inc (8QQ:STU) traded at 3.55, 8.55% above its 52-week low of 3.27, set on May 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.48 |
---|---|
High | 3.57 |
Low | 3.48 |
Bid | 3.52 |
Offer | 3.60 |
Previous close | 3.48 |
Average volume | 166.67 |
---|---|
Shares outstanding | 294.05m |
Free float | 211.77m |
P/E (TTM) | -- |
Market cap | 1.13bn USD |
EPS (TTM) | -0.5056 USD |
Data delayed at least 15 minutes, as of May 23 2024.
More ▼